IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the initiation of the Phase 2 portion of a global, open-label, randomized clinical trial studying the...
The recent strong funding support for Alzheimer’s science at NIA is a wonderful opportunity. But this exciting surge in clinical research brings with it a burgeoning demand for clinical research volunteers, and NIA is eager to assist investigators in achieving their...
— Mallinckrodt’s CONFIRM study is evaluating the efficacy and safety of terlipressin in hepatorenal syndrome type 1 — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that the company has achieved...
A new clinical trial at The Ohio State University Wexner Medical Centerand two other sites is testing an innovative procedure that may provide hope in the fight against Alzheimer’s disease. The non-invasive procedure uses low-intensity focused ultrasound to open the...
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company has completed dosing cohort 1 and treated the first patient in cohort 2 in an ongoing Phase 1/2 clinical trial evaluating ABO-101, its novel...
A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide) plus dexamethasone, for the treatment of relapsed or refractory multiple myeloma. The study,...
Email
Text